title: Cancer as a moving target: understanding the composition and rebound growth kinetics of recurrent tumors.
abstract: We introduce a stochastic branching process model of diversity in recurrent tumors whose growth is driven by drug resistance. Here, an initially declining population can escape certain extinction via the production of mutants whose fitness is drawn at random from a mutational fitness landscape. Using a combination of analytical and computational techniques, we study the rebound growth kinetics and composition of the relapsed tumor. We find that the diversity of relapsed tumors is strongly affected by the shape of the mutational fitness distribution. Interestingly, the model exhibits a qualitative shift in behavior depending on the balance between mutation rate and initial population size. In high mutation settings, recurrence timing is a strong predictor of the diversity of the relapsed tumor, whereas in the low mutation rate regime, recurrence timing is a good predictor of tumor aggressiveness. Analysis reveals that in the high mutation regime, stochasticity in recurrence timing is driven by the random survival of small resistant populations rather than variability in production of resistance from the sensitive population, whereas the opposite is true in the low mutation rate setting. These conclusions contribute to an evolutionary understanding of the suitability of tumor size and time of recurrence as prognostic and predictive factors in cancer.
authors: School of Mathematics, University of Minnesota Minneapolis, MN, USA.
authors: Jasmine
authors: J
authors: Foo
authors: Kevin
authors: K
authors: Leder
authors: Shannon M
authors: SM
authors: Mumenthaler
keywords: biomedicine; evolutionary theory; population genetics – theoretical
references: Chest. 2003 Nov;124(5):1828-33
references: 14605056
references: Cancer Res. 2005 Sep 15;65(18):8111-7
references: 16166284
references: Nat Rev Cancer. 2006 Dec;6(12):924-35
references: 17109012
references: Nat Rev Genet. 2005 Jun;6(6):451-64
references: 15883588
references: Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11
references: 15329413
references: Methods Enzymol. 2009;467:23-57
references: 19897088
references: Math Biosci. 2000 Mar;164(1):17-38
references: 10704636
references: Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):E2127-33
references: 22773810
references: J Natl Cancer Inst. 1999 Mar 17;91(6):523-8
references: 10088622
references: Blood. 1999 Sep 15;94(6):2056-64
references: 10477735
references: Nature. 2012 Jun 28;486(7404):537-40
references: 22722843
references: Genetics. 2011 Jun;188(2):461-77
references: 21406679
references: Cancer Res. 2007 Dec 15;67(24):11471-5
references: 18089772
references: Nat Methods. 2012 Sep;9(9):910-2
references: 22863882
references: N Engl J Med. 2012 Mar 8;366(10):883-892
references: 22397650
references: Mol Cancer. 2010 Apr 12;9:75
references: 20385023
references: PLoS One. 2011;6(11):e27682
references: 22140458
references: Math Biosci. 2000 Dec;168(2):187-200
references: 11121565
references: Proc Biol Sci. 2003 Dec 22;270(1533):2573-8
references: 14728779
references: Proc Natl Acad Sci U S A. 2006 Dec 19;103(51):19466-71
references: 17164333
references: Clin Cancer Res. 2011 Dec 15;17(24):7808-15
references: 21976538
references: Cancer Treat Rep. 1983 Oct;67(10):923-31
references: 6627236
references: Theor Popul Biol. 2007 Dec;72(4):523-38
references: 17915274
references: Theor Popul Biol. 2010 Aug;78(1):54-66
references: 20488197
references: Science. 2002 Aug 16;297(5584):1183-6
references: 12183631
references: Biol Direct. 2010 Apr 20;5:25
references: 20406443
references: Science. 2008 Aug 22;321(5892):1081-4
references: 18719282
references: Nature. 2001 Nov 1;414(6859):105-11
references: 11689955
references: J Thorac Oncol. 2008 Jul;3(7):781-92
references: 18594326
references: Chest. 2005 Nov;128(5):3255-60
references: 16304270
references: Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9714-9
references: 15980154
references: Cancer Res. 2007 Aug 1;67(15):7319-26
references: 17671201
references: Cancer Cell. 2010 Jan 19;17(1):77-88
references: 20129249
references: Clin Pharmacol Ther. 2009 Aug;86(2):167-74
references: 19440187
references: Cancer Res. 1987 Jan 15;47(2):407-9
references: 3466691
references: Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1727-33
references: 526911
references: Cancer Res. 2012 Jul 1;72(13):3302-11
references: 22552292
references: J Clin Invest. 2011 Jan;121(1):384-95
references: 21157036
references: Clin Cancer Res. 2004 Dec 15;10(24):8177-84
references: 15623592
references: Genetics. 2007 Dec;177(4):2209-21
references: 18073428
references: Nature. 1993 Jun 10;363(6429):558-61
references: 8505985
references: Cancer Res. 2011 Sep 15;71(18):5955-60
references: 21896640
references: Nature. 2012 Jan 11;481(7382):506-10
references: 22237025
references: Bull Math Biol. 1986;48(3-4):279-92
references: 3828558
references: Curr Pharm Des. 2006;12(3):261-71
references: 16454743